DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 50-443/S-035

Bristol-Myers Squibb Company
P.O. Box 4000
Princeton, NJ 08543-4000

Attention: Steven J. Knapp
Executive Director, Life Cycle Management

Dear Mr. Knapp:

Please refer to your supplemental new drug application dated January 9, 2003, received January 10, 2003, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Blenoxane® (bleomycin sulfate for injection, USP).

This supplemental new drug application provides for the addition of a **Geriatric Use** subsection to the package insert.

We completed our review of this application and it is approved, effective on the date of this letter, for use as recommended in the submitted labeling text and with the minor editorial revision listed below.

> The **References** section should be updated to include the following reference as #1 and re-numbered as appropriate.
>
> "ONS Clinical Practice Committee. Cancer Chemotherapy Guidelines and Recommendations for Practice. Pittsburgh, PA: Oncology Nursing Society; 1999:32-41."

The final printed labeling (FPL) must be identical, and include the minor editorial revision indicated, to the submitted labeling (package insert submitted January 9, 2003). These revisions are terms of the approval of this application.

Please submit the FPL electronically according to the guidance for industry titled Providing Regulatory Submissions in Electronic Format – NDA. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved supplement NDA 50-443/S-035." Approval of this submission by FDA is not required before the labeling is used.

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Christy Cottrell, Consumer Safety Officer, at (301) 594-5761.

Sincerely,

{See appended electronic signature page}

Richard Pazdur, M.D.
Director
Division of Oncology Drug Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

Enclosure

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Richard Pazdur

3/21/03 03:42:09 PM